News Column

Data on Inflammation Described by Researchers at Washington University

June 6, 2014



By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on Inflammation is now available. According to news reporting originating from St. Louis, Missouri, by NewsRx correspondents, research stated, "The airway provides a direct route for administration of nanoparticles bearing therapeutic or diagnostic payloads to the lung, however optimization of nanoplatforms for intracellular delivery remains challenging. Poly(ethylene glycol) (PEG) surface modification improves systemic performance but less is known about PEGylated nanoparticles administered to the airway."

Our news editors obtained a quote from the research from Washington University, "To test this, we generated a library of cationic, shell crosslinked knedel-like nanoparticles (cSCKs), including PEG (1.5 kDa PEG; 2, 5, 10 molecules/polymer arm) on the outer shell. Delivery of PEGylated cSCK to the mouse airway showed significantly less inflammation in a PEG dose-dependent manner. PEGylation also enhanced the entry of cSCKs in lung alveolar epithelial cells and improved surfactant penetration. The PEGylation effect could be explained by the altered mechanism of endocytosis. While non-PEGylated cSCKs used the clathrin-dependent route for endocytosis, entry of PEGylated cSCK was clathrin-independent. Thus, nanoparticle surface modification with PEG represents an advantageous design for lung delivery."

According to the news editors, the research concluded: "In this study, the effects of PEGylation were studied on cross linked knedel-like nanoparticles in drug delivery through the lungs, demonstrating less airway inflammation in the studied model than with non-PEGylated nanoparticles, which suggests an overall favorable profile of PEGylated nanoparticles for alveolar delivery."

For more information on this research see: PEGylation of cationic, shell-crosslinked-knedel-like nanoparticles modulates inflammation and enhances cellular uptake in the lung. Nanomedicine, 2013;9(7):912-22. (Elsevier - www.elsevier.com; Nanomedicine - www.elsevier.com/wps/product/cws_home/703416)

The news editors report that additional information may be obtained by contacting A. Ibricevic, Dept. of Internal Medicine, Washington University, St Louis, Missouri, United States. Additional authors for this research include S.P. Guntsen, K. Zhang, R. Shrestha, Y. Liu, J.Y. Sun, M.J. Welch, K.L. Wooley and S.L Brody (see also Inflammation).

Keywords for this news article include: Missouri, St. Louis, Inflammation, Nanoparticle, United States, Nanotechnology, Emerging Technologies, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Health & Medicine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters